Skip to main content
. 2023 May 29;15(11):2958. doi: 10.3390/cancers15112958

Figure 1.

Figure 1

Novel investigational agents. ATM—ataxia telangiectasia mutated kinase, ATR—ataxia telangiectasia and Rad3 related, CDK—Cyclin dependent kinase, CHK—check point kinase, FLT3—FMS like tyrosine kinase, MDM—Mouse Double Minute, NEDD8—Neural cell developmentally downregulated 8, PD—L Programmed cell death ligand, PLK—Polo like Kinase, RBM-RNA-binding motif protein, SIRPα- signal regulatory protein alpha, ***—variable fusion partner.